The force awakens: metastatic dormant cancer cells

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

(2019) Gabriel Mak et al.   BRITISH JOURNAL OF CANCER

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

(2019) Hao Wang et al.   Journal of Hematology & Oncology

A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib

(2019) Veronica A Guerra et al.   BLOOD

Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers

(2019) Yves Lecarpentier et al.   Frontiers in Oncology

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

(2019) David E. Gerber et al.   LUNG CANCER

A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer

(2018) Emerson Y. Chen et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

(2018) Niaz Mahmood et al.   Frontiers in Oncology

Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors

(2018) Shiva Shrotriya et al.   PLoS One

The role of cellular reactive oxygen species in cancer chemotherapy

(2018) Haotian Yang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease

(2018) Kendra Sweet et al.   LEUKEMIA RESEARCH

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

(2018) Qiang Lan et al.   ONCOGENE

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

(2018) Matthew J. Reilley et al.   Journal for ImmunoTherapy of Cancer

Innate and acquired immune surveillance in the postdissemination phase of metastasis

(2017) Hugo Gonzalez et al.   FEBS Journal

Significance of Monocyte Counts at Recurrence on Survival Outcome of Women With Endometrial Cancer

(2017) Hiroko Machida et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)

(2017) Martin J. Edelman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC).

(2017) M. B. Sawyer et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT).

(2017) R. C. Coombes et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

(2016) J. C. Soria et al.   ANNALS OF ONCOLOGY

Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT

(2016) Srinivas Malladi et al.   CELL

Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling

(2016) Hua Gao et al.   CELL

Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer

(2016) M. Hussain et al.   CLINICAL CANCER RESEARCH

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

(2016) B. Milojkovic Kerklaan et al.   INVESTIGATIONAL NEW DRUGS

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

(2016) Srdan Verstovsek et al.   Journal of Hematology & Oncology

Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells

(2016) Kyle K. Payne et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis

(2016) Sebastian R. Nielsen et al.   NATURE CELL BIOLOGY

T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells

(2016) Prachi Namjoshi et al.   Oncotarget

Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow

(2016) Kenji Yumoto et al.   Scientific Reports

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies

(2015) A. L. Wong et al.   ANNALS OF ONCOLOGY

Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy

(2015) R. Hughes et al.   CANCER RESEARCH

Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

(2015) Michinori Ogura et al.   CANCER SCIENCE

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors

(2015) Suzanne F. Jones et al.   INVESTIGATIONAL NEW DRUGS

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

(2015) Herbert I. Hurwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients withKRASwild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial

(2014) E. Élez et al.   ANNALS OF ONCOLOGY

The Inherent Premise of Immunotherapy for Cancer Dormancy

(2014) M. H. Manjili   CANCER RESEARCH

NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin-Aromatase Interactions

(2014) L. W. Bowers et al.   CANCER RESEARCH

Modulation of the Tumor Cell Phenotype by IFN-  Results in Resistance of Uveal Melanoma Cells to Granule-Mediated Lysis by Cytotoxic Lymphocytes

(2014) K. Hallermalm et al.   JOURNAL OF IMMUNOLOGY

Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy

(2013) B. Boyerinas et al.   BLOOD

Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

(2013) V Heinemann et al.   BRITISH JOURNAL OF CANCER

Molecular Pathways: MERTK Signaling in Cancer

(2013) C. T. Cummings et al.   CLINICAL CANCER RESEARCH

TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling

(2013) Paloma Bragado et al.   NATURE CELL BIOLOGY

IFN-γ Rα Is a Key Determinant of CD8+ T Cell-Mediated Tumor Elimination or Tumor Escape and Relapse in FVB Mouse

(2013) Maciej Kmieciak et al.   PLoS One

A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer

(2012) A. Heidenreich et al.   ANNALS OF ONCOLOGY

EMT and Dissemination Precede Pancreatic Tumor Formation

(2012) Andrew D. Rhim et al.   CELL

Randomized phase II trial of sulindac for lung cancer chemoprevention

(2012) Paul J. Limburg et al.   LUNG CANCER

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma

(2011) S O'Day et al.   BRITISH JOURNAL OF CANCER

Macrophage Binding to Receptor VCAM-1 Transmits Survival Signals in Breast Cancer Cells that Invade the Lungs

(2011) Qing Chen et al.   CANCER CELL

Cancer Invasion and the Microenvironment: Plasticity and Reciprocity

(2011) Peter Friedl et al.   CELL

Tumor Metastasis: Molecular Insights and Evolving Paradigms

(2011) Scott Valastyan et al.   CELL

Phase I Study of E7820, an Oral Inhibitor of Integrin  -2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

(2011) M. Mita et al.   CLINICAL CANCER RESEARCH

ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease

(2011) Maria Soledad Sosa et al.   CLINICAL CANCER RESEARCH

 1-Integrin: A Potential Therapeutic Target in the Battle against Cancer Recurrence

(2011) D. Barkan et al.   CLINICAL CANCER RESEARCH

A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer

(2011) Katherine M. Bell-McGuinn et al.   GYNECOLOGIC ONCOLOGY

Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone

(2011) Aya Kobayashi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

(2011) Bin-Zhi Qian et al.   NATURE

Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases

(2010) Mark A ROSENTHAL et al.   Asia-Pacific Journal of Clinical Oncology

Metastatic Growth from Dormant Cells Induced by a Col-I-Enriched Fibrotic Environment

(2010) D. Barkan et al.   CANCER RESEARCH

How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?

(2010) Yohannes Mebratu et al.   CELL CYCLE

Reactive oxygen species in cancer

(2010) Geou-Yarh Liou et al.   FREE RADICAL RESEARCH

Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

(2010) Ajjai Alva et al.   INVESTIGATIONAL NEW DRUGS

Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma

(2010) Jo Eyles et al.   JOURNAL OF CLINICAL INVESTIGATION

Computational Identification of a p38SAPK-Regulated Transcription Factor Network Required for Tumor Cell Quiescence

(2009) A. P. Adam et al.   CANCER RESEARCH

GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche

(2009) Yusuke Shiozawa et al.   EXPERIMENTAL HEMATOLOGY

Chronic Inflammation and Breast Cancer Recurrence

(2009) Steven W. Cole   JOURNAL OF CLINICAL ONCOLOGY

Integrin  1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs

(2009) T. Shibue et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Metastatic Outgrowth from Single Dormant Tumor Cells by Targeting the Cytoskeleton

(2008) D. Barkan et al.   CANCER RESEARCH

Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds  5 1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

(2008) A. D. Ricart et al.   CLINICAL CANCER RESEARCH

Immune-mediated dormancy: an equilibrium with cancer

(2008) Michele W. L. Teng et al.   JOURNAL OF LEUKOCYTE BIOLOGY

ATF6 -Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo

(2008) D. M. Schewe et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA